Literature DB >> 22664633

The best method for dose escalation: Prostate brachytherapy.

Gerard Morton1.   

Abstract

Year:  2012        PMID： 22664633      PMCID： PMC3367017          DOI： 10.5489/cuaj.12121

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  24 in total

Review 1.  Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review.

Authors:  Raveendhara R Bannuru; Tomas Dvorak; Ndidiamaka Obadan; Winifred W Yu; Kamal Patel; Mei Chung; Stanley Ip
Journal:  Ann Intern Med       Date:  2011-06-06       Impact factor: 25.391

2.  Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?

Authors:  Gerard Morton; Andrew Loblaw; Patrick Cheung; Ewa Szumacher; Manraj Chahal; Cyril Danjoux; Hans T Chung; Andrea Deabreu; Alexandre Mamedov; Liying Zhang; Raxa Sankreacha; Eric Vigneault; Colvin Springer
Journal:  Radiother Oncol       Date:  2011-09-14       Impact factor: 6.280

3.  Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience.

Authors:  John E Sylvester; Peter D Grimm; Jason Wong; Robert W Galbreath; Gregory Merrick; John C Blasko
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-23       Impact factor: 7.038

4.  High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.

Authors:  D Jeffrey Demanes; Alvaro A Martinez; Michel Ghilezan; Dennis R Hill; Lionel Schour; David Brandt; Gary Gustafson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-09       Impact factor: 7.038

5.  Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.

Authors:  Nelson N Stone; Mariana M Stone; Barry S Rosenstein; Pam Unger; Richard G Stock
Journal:  J Urol       Date:  2010-12-17       Impact factor: 7.450

6.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.

Authors:  Louis Potters; Carol Morgenstern; Emil Calugaru; Paul Fearn; Anup Jassal; Joseph Presser; Edward Mullen
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

7.  Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results.

Authors:  Fabio L Cury; Marie Duclos; Armen Aprikian; Horacio Patrocinio; Wassim Kassouf; George Shenouda; Sergio Faria; Marc David; Luis Souhami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-07-23       Impact factor: 7.038

8.  Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience.

Authors:  André-Guy Martin; Jean Roy; Luc Beaulieu; Jean Pouliot; François Harel; Eric Vigneault
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-02       Impact factor: 7.038

9.  Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

Authors:  Razvan M Galalae; Alvaro Martinez; Tim Mate; Christina Mitchell; Gregory Edmundson; Nils Nuernberg; Stephen Eulau; Gary Gustafson; Michael Gribble; Gyoergy Kovács
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

10.  Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.

Authors:  Al V Taira; Gregory S Merrick; Robert W Galbreath; Kent E Wallner; Wayne M Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-19       Impact factor: 7.038
View more
  5 in total

Review 1.  Artificial intelligence in brachytherapy: a summary of recent developments.

Authors:  Susovan Banerjee; Shikha Goyal; Saumyaranjan Mishra; Deepak Gupta; Shyam Singh Bisht; Venketesan K; Kushal Narang; Tejinder Kataria
Journal:  Br J Radiol       Date:  2021-04-29       Impact factor: 3.629

2.  Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy.

Authors:  David Buchser; Alfonso Gomez-Iturriaga; J Ignacio Rodriguez Melcon; Francisco Casquero; Roberto Llarena; Jon Cacicedo; Pedro Bilbao
Journal:  J Contemp Brachytherapy       Date:  2016-12-06

3.  Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study.

Authors:  Steven Gresswell; Rodney E Wegner; Day Werts; Ralph Miller; Russell Fuhrer
Journal:  Adv Radiat Oncol       Date:  2016-08-18

4.  A case of CRPC with multiple bladder invasions treated with EBRT followed by HDR-BT boost.

Authors:  Yoshiaki Takagawa; Jun Itami
Journal:  BJR Case Rep       Date:  2022-03-09

5.  Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy.

Authors:  Alfonso Gomez-Iturriaga; Juanita Crook; Francisco Casquero; Claudia Carvajal; Arantxa Urresola; Begoña Canteli; Ana Ezquerro; Eduardo Hortelano; Jon Cacicedo; Jose Maria Espinosa; Fernando Perez; Pablo Minguez; Pedro Bilbao
Journal:  J Contemp Brachytherapy       Date:  2014-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.